Factors affecting response of chemotherapy in women with ovarian cancer

Chemotherapy plays an important role in the treatment of ovarian cancer. Patients' response to chemotherapy is determined by a variety of acknowledged factors, but one might expect that many of them are yet to be described. The aim of this paper was to present the most essential yet still to be generally assessed in clinical practice, factors, which include: E-cadhedrin, hypoxia inducible factor alpha, survivin, COX-2, clusterin, BRCA1 protein, TP53 protein, YY1 protein, multidrug resistance protein, and interleukin-8.

Ovarian cancer; Chemotherapy; Factors affecting chemotherapy

[1] Skubitz A.P.: “Adhesion molecules”. Cancer Treat. Res., 2002, 107, 305.

[2] Sawada K., Mitra A.K., Radjabi A.R., Bhaskar V., Kistner E.O.: “Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin which is a therapeutic target”. Cancer Res., 2008, 68, 2329.

[3] Ho C.M., Chen W.F., Lin M.C., Chen T.C., Huang S.H., Liu F.S.: “Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma”. Int. J. Gynecol. Cancer, 2010, 20, 1490.

[4] Semenza G.: “Targeting HFI-1 for cancer therapy”. Nature Rev. Cancer, 2003, 10, 721.

[5] Powis G., Kirkpatrick L.: “Hypoxia inducible factor-1 alpha as a cancer drug target”. Mol. Cancer Ther., 2004, 647.

[6] Ding Z., Yang L., Xie X., Pan F., Li J., He J., Liang H.: “Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells”. J. Cancer Res. Clin. Oncol., 2010, 136, 1697.

[7] Huang L., Ao Q., Zhang Q. Yang X., Xing H., Li F. et al.: “Hypoxia induces paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha”. J. Cancer Res. Clin. Oncol., 2010, 136, 447.

[8] Shimogai R., Kigawa J., Itamochi H., Iba T., Kanamori Y., Oishi T. et al.: “Expression of hypoxia-inducible factor 1 alpha gene affects the outcome in patients with ovarian cancer”. Int. J. Gynecol. Cancer, 2008, 18, 499.

[9] Altieri D.C.: “Survivin, versatile modulation of cell division and apoptosis in cancer”. Oncogene, 2003, 22, 8581.

[10] Shin S., Sung B.J., Cho Y.S., Kim H.J., Ha N.C., Hwang J.I. et al.: “An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7”. Biochemistry, 2001, 40, 117.

[11] Urbaniak J.: “Expression of survivin in human cancer”. Adv. Clin. Exp. Med., 2004, 13, 1037.

[12] Felisiak-Goła˛bek A., Rembiszewska A., Rzepecka I.K., Szafron L., Madry R., Murawska M. et al.: “Nuclear survivin expresion is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients”. J. Ovarian Res., 2011, 4, 1.

[13] Kalin´ski P.: “Regulation of immune responses by prostaglandin E2”. J. Immunol., 2012, 188, 21.

[14] Toomey D.P., Murphy J.E., Colon K.C.: “COX-2, VEGF and tumor angiogenesis”. Surgeon, 2009, 7, 174.

[15] Seo S.S., Song Y.S., Kang D.H., Park J.A., Bang Y.J., Kang S.B., Lee H.P.: “Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer”. Gynecol. Oncol., 2004, 92, 927.

[16] Steffensen K.D., Waldstrøm M., Jeppesen U., Jakobsen E., Brandslund I., Jakobsen A.: “The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer”. Int. J. Gynecol. Cancer, 2007, 17, 798.

[17] Wang M., He Y., Shi L., Shi C.: “Multivariate analysis by COX proportional hazards model on prognosis of patients with epithelial ovarian cancer”. Eur. J. Gynecol. Oncol., 2011, 32, 171.

[18] Ferrandina G., Lauriola L., Zannoni G.F., Fagotti A., Fanfani F., Legge F. et al.: “Increased cyclooxygenase - 2 (COX2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients”. Ann. Oncol., 2002, 13, 1205.

[19] Shannan B., Seifert M., Leskov K., Willis J., Boothman D., Tilgen W., Reichrath J.: “Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer”. Cell Death Differ., 2006, 13, 12.

[20] Yang G.F., Li X.M., Xie D.: “Overexpresion of clusterin in ovarian cancer is correlated with impaired survival”. Int. J. Gynecol. Cancer, 2009, 19, 1342.

[21] Wei L., Xue T., Wang J., Chen B., Lei Y., Huang Y. et al.: “Roles of clusterin in progresion, chemoresistance and metastasis of human ovarian cancers”. Int. J. Cancer, 2009, 125, 791.

[22] Hassan M.K., Watari H., Christenson L., Bettuzzi S., Sakuragi N.: “Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel”. Tumor Biol., 2011, 32, 1031.

[23] Park D.C., Yeo S.G., Wilson M.R., Yerburg J.J., Kwong J., Welch W.R. et al.: “Clusterin interacts with paclitaxel and confer paclitaxel resistance in ovarian cancer”. Neoplasia, 2008, 10, 964.

[24] Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S.: “A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1”. Science, 1994, 266, 66.

[25] Quinn J.E., James C.R., Stewart G.E., Mulligan J.M., White P., Chang G.K., et al.: “BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy”. Clin. Cancer Res., 2007, 13, 7413.

[26] Quinn J.E., Kennedy R.D., Mullan B.B., Gilmore P.M., Carty M., Johnston P.G., Harkin D.P.: “BRCA1 function as a differential modulator of chemotherapy-induced apoptosis”. Cancer Res., 2003, 63, 6221.

[27] Fong P.C., Yap T.A., Boss D.S., Carden C.P., Mergui-Roelvink M., Gourley C. et al.: “Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval”. J. Clin. Oncol., 2010, 28, 2512.

[28] Cassinelli G., Supino R., Perego P., Polizzi D., Lanzi C., Pratesi G., Zunino F.: “A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes”. Int. J. Cancer, 2001, 92, 738.

[29] Ueno Y., Enomoto T., Otsuki Y., Sugita N., Nakashima R., Yoshino K., Kuragaki C. et al.: “Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin”. Cancer Lett., 2006, 241, 289.

[30] de Graeff P., Crijns AP., de Jong S., Boezen M., Post W.J., de Vries E.G. et al.: “Modest effect of p53, EGFR and HER-2/neu in prognosis in epithelial ovarian cancer: a meta-analysis”. Br. J. Cancer, 2009, 101, 149.

[31] Shi Y., Seto E., Chang LS., Shenk T: “Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein”. Cell, 1991, 67, 377.

[32] Matsumura N., Huang Z., Baba T., Lee P.S., Barnett J.C., Mori S., Chang J.T. et al.: “Yin yang 1 modulates taxane response in epithelial ovarian cancer”. Mol. Cancer Res., 2009, 7, 210.

[33] Ieiri I., Takane H., Otsubo K.: “The MDR1 (ABCB1) gene polymorphism and its clinical implications”. Clin. Pharmacokinet., 2004, 43, 553.

[34] Sugawara I., Shinichi A., Scheper R.: “Lung resistance protein (LPR) expression in human normal tissues in comparison with that of MDR1 nad MRP”. Cancer Lett., 1997, 112, 23.

[35] Sarkadi B., Özvegy-Laczka C., Német K.: “ABCG2 – a transporter for all seasons”. FEBS Lett., 2004, 567, 116.

[36] Chen C., Clark D, Ueda K., Pastan I., Gottesman M.M., Roninson I.B.: “Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoprotein”. J. Biol. Chem., 1990, 265, 506.

[37] Bourhis J., Goldstein L.: “Expression of a human multidrug resistance gene in ovarian carcinoma”. Cancer Res., 1989, 49, 5062.

[38] Cordon-Cardo C., O’Brien J., Boccia J.: “Expression of multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues”. J. Histochem. Cytochem., 1990, 38, 1277.

[39] Thiebaut F., Tsuruo T., Hamada H.: “Cellular localisation of the multi-drug resistance gene product P-glycoprotein in normal human tissues”. Proc. Natl. Acad. Sci USA, 1987, 84, 7735.

[40] Valera E., Scrideli C., Queiroz R., Mori B.M., Tone L.G.: “Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in chilchood acute lymphblastic leukemia”. São Paulo Med. J., 2004, 122, 166.

[41] Meschini S., Marra M., Calcabrini A.: “Role of lung resistancerelated protein (LRP) in the drug sensitivity of cultured tumor cells”. Toxicol. in Vitro, 2002, 16, 389.

[42] Doyle L., Yang W., Abruzzo L.: “A multidrug resistence transporter from human MCF-7 breast cancer cell”. Proc. Natl. Acad Sci. USA, 1998, 95, 156.

[43] Fojo A., Ueda K., Salmon D.: “Expression of multidrug-resistance gene in human tumors and tissues”. Proc, Natl, Acad, Sci USA, 1987, 84, 265.

[44] Miedzinska-Maciejewska M., Wcisło G.: “Mechanism of multidrug resistance of ovarian cancer”. Przegl. Lek., 2002, 59, 854.

[45] Zee A., Hollema H., Suurmejer A.: “Value of P-glycoprotein glutathione S transferase pi, c-arb-2 and p53 as prognostic factors in ovarian carcinomas”. J. Clin. Oncol., 1995, 13, 70.

[46] Rein D.T., Volkmer A., Beyer I.M., Curiel D.T., Janni W., Dragoi A., Hess A.P. et al.: “Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus”. Gynecol. Oncol., 2011, 123(1), 138.

[47] Matsushima K., Oppenheim J.J.: “Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL 1 and TNF”. Cytokine, 1989, l, 2.

[48] Li A., Varney M.L., Valasek J., Godfrey M., Dave B.J., Singh R.K.: “Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis”. Angiogenesis, 2005, 8, 63.

[49] Merritt WM., Lin YG., Spannuth WA., Fletcher M.S., Kamat A.A., Han L.Y. et al.: “Effect of Interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth”. J. Natl. Cancer Inst., 2008, 100, 359.

[50] Wang Y., Qu Y., Niu X.L., Sun W.J., Zhang X.L., Li L.Z.: “Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells”. Cytokine, 2011, 56, 365.